Folia Pharmacologica Japonica最新文献_第3页

[The role of vendors in the democratization of AI-challenges and collaboration in the application of image analysis technology to drug discovery processes]. [供应商在人工智能民主化中的作用，挑战和在图像分析技术应用于药物发现过程中的合作]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24109

Yuki Kato, Hiroki Kawai

引用次数: 0

[Involvement of chemokines and these receptors in glioblastoma]. 趋化因子和这些受体在胶质母细胞瘤中的作用。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.25005

Yuta Hara, Kazuhiko Matsuo, Takashi Nakayama

{"title":"[Involvement of chemokines and these receptors in glioblastoma].","authors":"Yuta Hara, Kazuhiko Matsuo, Takashi Nakayama","doi":"10.1254/fpj.25005","DOIUrl":"https://doi.org/10.1254/fpj.25005","url":null,"abstract":"Chemokines are a group of cytokines which are involved in the migration of immune cells as well as other cell types such as endothelial cells. These molecules normally regulate the homeostasis in our body's immune system. Furthermore, it has been reported that chemokines mediate the onset and progression of various diseases including allergic diseases, autoimmune diseases, and cancers through the recruitment of immune cells to inflammatory sites. Glioblastoma is one of the primary brain tumors with a significantly poor prognosis. Similarly to other tumors, it has been observed that various immune cells infiltrate into the brain tumor tissues. However, the details of the mechanisms remain unclear. At present, cancer immunotherapy is vigorously researched, and is proved to be effective for many cancers. Unfortunately, the effectiveness of cancer immunotherapy has not yet been shown in glioblastoma. Chemokine is thought to be one of the important factors for cancer immunotherapy. Therefore, understanding the role of chemokines in glioblastoma is considered to be beneficial for the development of cancer immunotherapy. In this review, we overview the role of chemokines and these receptors in glioblastoma.","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 3","pages":"172-176"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[AlphaFold: a revolutionary AI-based protein structure prediction system and its applications in drug discovery research]. [AlphaFold：革命性的基于人工智能的蛋白质结构预测系统及其在药物发现研究中的应用]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.25023

Kazuharu Furutani, Satomi Kita

引用次数: 0

[NAD⁺ metabolism as a target for anti-aging]. [NAD+代谢作为抗衰老的靶标]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24072

Hitoshi Uchida, Takashi Nakagawa

{"title":"[NAD+ metabolism as a target for anti-aging].","authors":"Hitoshi Uchida, Takashi Nakagawa","doi":"10.1254/fpj.24072","DOIUrl":"10.1254/fpj.24072","url":null,"abstract":"Aging is a physiological process caused by various genetic and environmental factors. Recently, it has been proposed that the disturbance of the nutritional-metabolic sensing pathway is one of the aging characteristics. In particular, nicotinamide adenine dinucleotide (NAD+) plays an important role in this pathway and is considered the regulator of aging. NAD+ regulates an energy metabolism as a co-factor and is also involved in various biological processes including transcription, stress responses, DNA repair, inflammatory responses as well as post-transcriptional modifications, as a substrate for sirtuins, poly ADP-ribose polymerase (PARP), and CD38. With age, DNA damage and chronic inflammation increase in organs, resulting in overconsumption of NAD+ via PARP and CD38. The reduced NAD+ levels decrease the activity of sirtuins and PARPs and impair energy metabolism, ultimately leading to aging and aging-related diseases. However, the precise metabolism of NAD+ in vivo and the mechanism of how NAD+ regulates aging remain elusive. Moreover, the clinical application of NAD+ supplementation therapy is still under development. In this review, we overview the NAD+ metabolism and its relation to aging. In addition, we describe the current issue and perspective of NAD+ supplementation therapy to promote a healthy lifespan.","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 4","pages":"268-273"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[2-oxoglutarate-dependent dioxygenase family as a molecular sensor for cellular oxygen and metabolic sensing]. [2-氧戊二酸依赖的双加氧酶家族作为细胞氧和代谢传感的分子传感器]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.25021

Koh Nakayama, Yoji Andrew Minamishima

引用次数: 0

[Application of neural organoids containing microglia to neurodegenerative disease research]. [含小胶质细胞的类神经器官在神经退行性疾病研究中的应用]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.25034

Koki Harada, Kazuyuki Takata

{"title":"[Application of neural organoids containing microglia to neurodegenerative disease research].","authors":"Koki Harada, Kazuyuki Takata","doi":"10.1254/fpj.25034","DOIUrl":"10.1254/fpj.25034","url":null,"abstract":"In recent years, the \"translational gap\" has become problematic in drug development, wherein promising results from animal experiments and in vitro tests fail to demonstrate the expected efficacy and safety in clinical trials. This translational gap has also impacted on the development of therapeutic agents for brain diseases, including Alzheimer's disease (AD). While microglia, which are immune cells in the brain, have gained attention as therapeutic targets of AD, the inter-species difference in microglia between humans and experimental model animals may cause this gap. To reveal the pathogenic mechanisms of AD and develop a therapeutic strategy, experimental models that appropriately reproduce pathological conditions using human-derived materials are required. Pluripotent stem cells can differentiate into various cells such as neurons and microglia. Therefore, it is expected that the creation of neural organoids from human pluripotent stem cells will enable the construction of a human-based analysis system that can reproduce three-dimensional brain structures and intercellular interactions, thereby overcoming the translational gap. Furthermore, combining patient-derived induced pluripotent stem cells and gene editing technology with neural organoid technology is leading to cutting-edge research. In this review, we introduce global research trends aimed at developing neural organoids containing microglia derived from human pluripotent stem cells and applying them to elucidate the pathogenesis and to develop therapeutic drugs for AD.","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 5","pages":"334-337"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Insulin signaling and neuropathological changes in Alzheimer's disease]. [阿尔茨海默病的胰岛素信号和神经病理变化]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.25019

Tomoko Wakabayashi

{"title":"[Insulin signaling and neuropathological changes in Alzheimer's disease].","authors":"Tomoko Wakabayashi","doi":"10.1254/fpj.25019","DOIUrl":"10.1254/fpj.25019","url":null,"abstract":"Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia. Its pathological features include abnormal aggregation of amyloid-β (Aβ) and tau proteins, neuronal loss, and brain atrophy. The \"amyloid hypothesis\" suggests that Aβ accumulation triggers disease progression, leading to the development of anti-Aβ antibody therapies. However, their effectiveness is limited once dementia has developed, highlighting the need for early intervention in the preclinical stage. This review focuses on type 2 diabetes (T2D) and insulin resistance as acquired risk factors for AD, summarizing epidemiological and experimental evidence on their impact on AD neuropathology. While early postmortem studies produced inconsistent results regarding the association between T2D, insulin resistance, and Aβ deposition, recent amyloid PET imaging studies have clarified this relationship in the human brain. Additionally, animal studies suggest that diet-induced insulin resistance promotes Aβ accumulation. Conversely, genetic disruption of insulin signaling molecules significantly suppresses Aβ pathology. These seemingly contradictory findings suggest that while reduced brain insulin signaling may inhibit Aβ pathology, peripheral metabolic disturbances associated with worsening insulin resistance may accelerate Aβ deposition. Understanding the multifaceted roles of insulin signaling and the molecular basis of these complex interactions is crucial for identifying new preventive and disease-modifying therapeutic targets. Advancing this knowledge is essential for developing innovative AD treatments.","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 5","pages":"324-328"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Promotion of the appropriate use of antimicrobial agents by utilizing medical big data]. [利用医疗大数据促进抗菌药物的合理使用]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24081

Masayuki Chuma, Mitsuhiro Goda, Hirofumi Hamano, Takahiro Niimura, Kenshi Takechi, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami, Keisuke Ishizawa, Yoshikazu Tasaki

{"title":"[Promotion of the appropriate use of antimicrobial agents by utilizing medical big data].","authors":"Masayuki Chuma, Mitsuhiro Goda, Hirofumi Hamano, Takahiro Niimura, Kenshi Takechi, Kenta Yagi, Yuki Izawa-Ishizawa, Yoshito Zamami, Keisuke Ishizawa, Yoshikazu Tasaki","doi":"10.1254/fpj.24081","DOIUrl":"https://doi.org/10.1254/fpj.24081","url":null,"abstract":"The global surge in antimicrobial resistance (AMR) highlights the critical need for the development of innovative therapies and the appropriate use of antimicrobial agents. Our research focused on preventing, managing, and mitigating the adverse effects of treatments for infection with methicillin-resistant Staphylococcus aureus. In this review, we present our investigations utilizing medical big data. The first study aimed to elucidate the relationship between renal outcome and survival following the onset of vancomycin-associated nephrotoxicity (VAN). An initial analysis using the US Food and Drug Administration Adverse Events Reporting System (FAERS) database revealed elevated mortality rates among patients with VAN compared with those without VAN, forming the basis for further investigation. A subsequent, more rigorous, retrospective analysis using electronic medical records confirmed that poor survival outcomes were significantly associated with non-recovery from VAN, particularly when progression to acute kidney injury of stage ≥2 occurred. Therefore, preventing progression to severe VAN is critical for enhancing survival outcomes. The second study investigated the relationship between statin use and daptomycin-related musculoskeletal adverse events. By employing a mixed-method approach combining meta-analysis with disproportionality analysis of the FAERS data, a significant association between statin therapy and daptomycin-related rhabdomyolysis was identified. This highlights the importance of cautious statin and daptomycin use, with careful consideration of potential safety risks. Each medical big-data database possesses unique characteristics that require careful consideration during analysis. The accurate interpretation of medical big data, coupled with its integration with complementary methodologies, will produce more robust and reliable research outcomes across diverse fields.","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"160 3","pages":"178-183"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Gene therapy for visual function recovery]. [视力恢复的基因治疗]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.24053

Kazuhiko Namekata, Xiaoli Guo, Chikako Harada, Takayuki Harada

引用次数: 0

[The efficacy of Sigma-1 receptor agonists in heart and renal diseases]. [Sigma-1受体激动剂治疗心脏和肾脏疾病的疗效]。

Folia Pharmacologica Japonica Pub Date : 2025-01-01 DOI: 10.1254/fpj.25039

Hideaki Tagashira

引用次数: 0